Literature DB >> 25037567

Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors.

Cornelia M Wilson1, Thomas Naves2, François Vincent3, Boris Melloni4, François Bonnaud4, Fabrice Lalloué2, Marie-Odile Jauberteau2.   

Abstract

The transfer of exosomes containing both genetic and protein materials is necessary for the control of the cancer cell microenvironment to promote tumor angiogenesis. The nature and function of proteins found in the exosomal cargo, and the mechanism of their action in membrane transport and related signaling events are not clearly understood. In this study, we demonstrate, in human lung cancer A549 cells, that the exosome release mechanism is closely linked to the multifaceted receptor sortilin (also called neurotensin receptor 3). Sortilin is already known to be important for cancer cell function. Here, we report for the first time its role in the assembly of a tyrosine kinase complex and subsequent exosome release. This new complex (termed the TES complex) is found in exosomes and results in the linkage of the two tyrosine kinase receptors TrkB (also known as NTRK2) and EGFR with sortilin. Using in vitro models, we demonstrate that this sortilin-containing complex exhibits a control on endothelial cells and angiogenesis activation through exosome transfer.
© 2014. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Angiogenesis; Cancer; EGFR; Exosome; NTRK2; Sortilin; TrkB

Mesh:

Substances:

Year:  2014        PMID: 25037567     DOI: 10.1242/jcs.149336

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  41 in total

Review 1.  Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept.

Authors:  M Borsotto; J Veyssiere; H Moha Ou Maati; C Devader; J Mazella; C Heurteaux
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

2.  Exosomes: nanoshuttles to the future of BioMedicine.

Authors:  Marco Ragusa; Davide Barbagallo; Michele Purrello
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer.

Authors:  Qianping Li; Weijie Ma; Tianhong Li
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Dark-Side of Exosomes.

Authors:  Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Viral effects on the content and function of extracellular vesicles.

Authors:  Nancy Raab-Traub; Dirk P Dittmer
Journal:  Nat Rev Microbiol       Date:  2017-06-26       Impact factor: 60.633

6.  Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells.

Authors:  Anne-Florence Blandin; Elisabete Cruz Da Silva; Marie-Cécile Mercier; Oleksandr Glushonkov; Pascal Didier; Stéphane Dedieu; Cristophe Schneider; Jessica Devy; Nelly Etienne-Selloum; Monique Dontenwill; Laurence Choulier; Maxime Lehmann
Journal:  Cell Mol Life Sci       Date:  2020-11-05       Impact factor: 9.261

Review 7.  Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

Authors:  Hussein Akil; Aurélie Perraud; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 8.  Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.

Authors:  Claudia Goettsch; Mads Kjolby; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-30       Impact factor: 8.311

Review 9.  Potential roles of tumor-derived exosomes in angiogenesis.

Authors:  Nils Ludwig; Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-26       Impact factor: 6.902

10.  Sortilin mediates vascular calcification via its recruitment into extracellular vesicles.

Authors:  Claudia Goettsch; Joshua D Hutcheson; Masanori Aikawa; Hiroshi Iwata; Tan Pham; Anders Nykjaer; Mads Kjolby; Maximillian Rogers; Thomas Michel; Manabu Shibasaki; Sumihiko Hagita; Rafael Kramann; Daniel J Rader; Peter Libby; Sasha A Singh; Elena Aikawa
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.